Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Program entities : Sanofi save search
MoonLake Immunotherapeutics Announces Positive Feedback from both FDA and EMA on Regulatory Path for the Phase 3 Program of the Nanobody® sonelokimab (SLK) in Hidradenitis Suppurativa (HS)
Published: 2024-02-26 (Crawled : 13:00) - globenewswire.com
MLTX | $43.19 -0.74% 31K
|
|
| O: 0.0%
H: 2.86%
C: 0.13%
SNYNF | News | $92.7 1.4K
|
Health Technology
|
| O: -0.82%
H: 0.0%
C: 0.0%
SNY | News | $45.56 -1.19% 910K
|
Health Technology
|
| O: 0.89%
H: 0.0%
C: 0.0%
nanobody fda positive ema program
Press Release: Peer support, flexible work arrangements, salary for a year: Sanofi launches global program for employees affected by cancer and critical illnesses
Published: 2024-02-05 (Crawled : 07:00) - globenewswire.com
SNY | News | $45.56 -1.19% 910K
|
Health Technology
|
| O: -1.85%
H: 0.0%
C: 0.0%
work cancer global program sanofi
Innate Pharma Announces U.S. FDA Lifts Partial Clinical Hold on Lacutamab Clinical Program
Published: 2024-01-04 (Crawled : 08:00) - biospace.com/
SNYNF | News | $92.7 1.4K
|
Health Technology
|
| O: 1.62%
H: 0.0%
C: 0.0%
SNY | News | $45.56 -1.19% 910K
|
Health Technology
|
| O: 1.12%
H: 0.93%
C: 0.77%
IPHA | $2.41 11K
|
Health Technology
|
| O: 6.47%
H: 3.65%
C: -2.36%
fda pharma program
First Wave BioPharma Announces Streamlining of Clinical Pipeline with Non-Binding Term Sheet to Sell Niclosamide IBD Program
Published: 2023-12-27 (Crawled : 11:00) - globenewswire.com
SNYNF | News | $92.7 1.4K
|
Health Technology
|
| O: 0.36%
H: 0.03%
C: 0.03%
FWBI | News | $2.9 5.5K
|
Manufacturing
|
| O: 251.76%
H: 11.79%
C: -57.4%
SNY | News | $45.56 -1.19% 910K
|
Health Technology
|
| O: 1.2%
H: 0.0%
C: 0.0%
first pipeline biopharma niclosamide program
Press Release: Sanofi announces end of program evaluating tusamitamab ravtansine after a 2L NSCLC Phase 3 trial did not meet a primary endpoint
Published: 2023-12-21 (Crawled : 07:00) - globenewswire.com
SNYNF | News | $92.7 1.4K
|
Health Technology
|
| O: -0.1%
H: 0.0%
C: 0.0%
SNY | News | $45.56 -1.19% 910K
|
Health Technology
|
| O: -0.08%
H: 0.0%
C: 0.0%
program trial sanofi
FDA Puts Clinical Hold on Roche BTK Inhibitor Multiple Sclerosis Program
Published: 2023-12-05 (Crawled : 13:30) - biospace.com/
SNYNF | News | $92.7 1.4K
|
Health Technology
|
| O: 0.27%
H: 0.12%
C: 0.12%
SNY | News | $45.56 -1.19% 910K
|
Health Technology
|
| O: -0.5%
H: 0.0%
C: 0.0%
fda sclerosis program roche
Dr. Alan Kivitz to Chair XBiotech’s Natrunix Program in Rheumatoid Arthritis
Published: 2023-11-14 (Crawled : 14:30) - globenewswire.com
XBIT | $8.1 -0.12% 34K
|
Health Technology
|
| O: 1.02%
H: 2.27%
C: -4.03%
SNY | News | $45.56 -1.19% 910K
|
Health Technology
|
| O: 0.68%
H: 0.0%
C: 0.0%
program
Pfizer and BioNTech Announce Positive Topline Data for mRNA-based Combination Vaccine Program Against Influenza and COVID-19
Published: 2023-10-26 (Crawled : 11:00) - globenewswire.com
PFE A | $25.325 -0.37% 15M
|
Health Technology
|
| O: -0.39%
H: 2.48%
C: 1.8%
SNY | News | $45.56 -1.19% 910K
|
Health Technology
|
| O: 0.09%
H: 0.0%
C: 0.0%
BNTX | $86.085 -0.37% 160K
|
Health Technology
|
| O: 0.99%
H: 1.81%
C: 0.47%
covid-19 vaccine positive influenza topline program
Recludix Pharma Presents Preclinical Data from its STAT3 Inhibitor Program at the International Conference of the Inflammation Research Association (IRA)
Published: 2023-10-17 (Crawled : 23:00) - biospace.com/
SNY | News | $45.56 -1.19% 910K
|
Health Technology
|
| O: -0.4%
H: 0.0%
C: 0.0%
pharma conference association international research preclinical program
BioNTech to Present Multiple Program Updates Across Modalities at ESMO Congress 2023
Published: 2023-10-16 (Crawled : 08:00) - globenewswire.com
SNY | News | $45.56 -1.19% 910K
|
Health Technology
|
| O: -0.26%
H: 0.0%
C: 0.0%
BNTX | $86.085 -0.37% 160K
|
Health Technology
|
| O: -5.24%
H: 1.85%
C: -1.2%
congress program
Innate Pharma Provides Update on Lacutamab Clinical Program
Published: 2023-10-05 (Crawled : 08:00) - biospace.com/
SNY | News | $45.56 -1.19% 910K
|
Health Technology
|
| O: 0.19%
H: 0.0%
C: 0.0%
IPHA | $2.41 11K
|
Health Technology
|
| O: -9.31%
H: 7.14%
C: 7.14%
pharma update program
ROME Therapeutics Closes Oversubscribed $72 Million Series B Extension to Support Advancement of Lead Program into Clinical Development for Autoimmune Disease
Published: 2023-09-12 (Crawled : 12:00) - biospace.com/
JNJ | News | $144.86 0.06% 2.8M
|
Health Technology
|
| O: 0.62%
H: 0.0%
C: 0.0%
SNY | News | $45.56 -1.19% 910K
|
Health Technology
|
| O: 0.77%
H: 0.0%
C: 0.0%
disease series extension program therapeutics
Neurophet, the first company in Korea, selected by Roche Diagnostics for Startup Creasphere's APAC innovation program
Published: 2023-09-05 (Crawled : 13:00) - prnewswire.com
SNY | News | $45.56 -1.19% 910K
|
Health Technology
|
| O: -0.93%
H: 0.0%
C: 0.0%
innovation program roche diagnostics
Launch of Insilico’s Phase II Program Highlights Generative AI Momentum
Published: 2023-08-14 (Crawled : 05:00) - biospace.com/
SNY | News | $45.56 -1.19% 910K
|
Health Technology
|
| O: 0.04%
H: 0.0%
C: 0.0%
momentum program
ALX Oncology Reports Second Quarter 2023 Financial Results and Provides Clinical Program Update
Published: 2023-08-10 (Crawled : 23:00) - biospace.com/
SNY | News | $45.56 -1.19% 910K
|
Health Technology
|
| O: 1.52%
H: 1.05%
C: 0.47%
ALXO | $15.99 -0.56% 260K
|
Commercial Services
|
| O: 1.0%
H: 4.17%
C: 0.0%
update program financial results
BioNTech and OncoC4 Initiate Pivotal Phase 3 Trial of BNT316/ONC-392 Program in Metastatic NSCLC
Published: 2023-06-29 (Crawled : 11:00) - globenewswire.com
SNY | News | $45.56 -1.19% 910K
|
Health Technology
|
| O: -1.86%
H: 0.0%
C: 0.0%
BNTX | $86.085 -0.37% 160K
|
Health Technology
|
| O: -0.33%
H: 1.5%
C: 0.42%
bnt316 program trial
Innate Pharma Announces Exclusive License of Antibodies to Takeda for Celiac Disease Research Program
Published: 2023-04-03 (Crawled : 07:00) - biospace.com/
SNYNF | News | $92.7 1.4K
|
Health Technology
|
| O: 0.23%
H: 0.0%
C: 0.0%
SNY | News | $45.56 -1.19% 910K
|
Health Technology
|
| O: -0.05%
H: 0.0%
C: 0.0%
IPHA | $2.41 11K
|
Health Technology
|
| O: 14.39%
H: 3.99%
C: -3.37%
pharma disease license research program
BioNTech Announces New ADS Repurchase Program
Published: 2023-03-28 (Crawled : 11:00) - globenewswire.com
SNY | News | $45.56 -1.19% 910K
|
Health Technology
|
| O: 2.06%
H: 0.0%
C: 0.0%
BNTX | $86.085 -0.37% 160K
|
Health Technology
|
| O: 0.36%
H: 1.06%
C: -0.85%
repurchase program
AlgoTx Raises €20M to Conduct ATX01’s Phase 2 Program in Peripheral Neuropathic Pain
Published: 2023-03-14 (Crawled : 11:00) - biospace.com/
SNYNF | News | $92.7 1.4K
|
Health Technology
|
| O: -1.13%
H: 0.0%
C: -0.22%
SNY | News | $45.56 -1.19% 910K
|
Health Technology
|
| O: -0.08%
H: 0.0%
C: 0.0%
atx01 program phase 2
Alnylam Announces 2023 Product and Pipeline Goals and Provides Program Updates at R&D Day
Published: 2022-12-15 (Crawled : 14:00) - biospace.com/
SNYNF | News | $92.7 1.4K
|
Health Technology
|
| O: -0.85%
H: 0.0%
C: 0.0%
SNY | News | $45.56 -1.19% 910K
|
Health Technology
|
| O: 0.04%
H: 0.0%
C: 0.0%
ALNY | $146.09 0.53% 59K
|
Health Technology
|
| O: -0.39%
H: 0.0%
C: -1.56%
day program
Gainers vs Losers
| 82% | 18% |
Top 10 Gainers
AGBA | $0.7995 99.88% 73M
|
Finance
BPTH | $6.21 91.67% 58M
|
Health Technology
INVO | $1.36 78.95% 3.6M
|
Health Technology
TIRX | $0.8258 70.34% 50M
|
ISPC | $0.307 44.13% 3.6M
|
Professional, Scientific, and T...
SINT | $0.0519 39.14% 350M
|
Health Technology
VTNR S | $1.295 32.25% 5.5M
|
Industrial Services
ALRN | $5.53 30.12% 250K
|
Health Technology
SMSI 4 | $2.53 29.74% 510K
|
Technology Services
HOLO | $2.86 27.68% 28M
|
Your saved searches
Save your searches and get alerts when important news are released.